Home » FORBES MEDI-TECH RECEIVES FDA CLEARANCE TO BEGIN CHOLESTEROL DRUG STUDY
FORBES MEDI-TECH RECEIVES FDA CLEARANCE TO BEGIN CHOLESTEROL DRUG STUDY
The FDA has informed Forbes Medi-Tech that it may proceed with its Phase II clinical trial of the cholesterol-lowering drug FM-VP4, as set forth in an investigational new drug application. Forbes plans to initiate the trial program later this month.
FM-VP4 is a cholesterol absorption inhibitor, a new class in cholesterol-lowering drugs. FM-VP4 has demonstrated significant cholesterol-lowering and anti-atherosclerotic properties in preclinical studies.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May